LLY
ELI LILLY & CoNYSEMarket price sits 49% above base IV — no margin of safety.
This scenario follows what most Wall Street analysts currently expect: Lilly keeps growing quickly for another two or three years as its weight-loss and diabetes treatments and a newly approved daily pill roll out around the world, then growth eases toward a more ordinary pace by the end of the decade while the company stays one of the most profitable large drugmakers.
Scouting report
OvervaluedA one-glance read on valuation, conviction, and risk.
Price is above even the bull case.
Base case $589.29 vs $1,148.84 price.
Source: base case IV vs market price
Confidence — bear: medium, base: medium, bull: low.
Source: research confidence per case
Valued today.
Source: valuation run date
Net debt of $34.1B (3.3% of market cap).
Source: base inputs + market cap
Bear-to-bull spread is 125.9% of the base case.
Source: bear/bull dispersion
Composed from the published valuation · price as of 2026-08-03 — educational, not investment advice.
Make it your own valuation. Create a free account to edit every assumption behind LLY's intrinsic value and test your own thesis.